Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis

Simple item page
dc.contributor.authorConradie, Francesca
dc.contributor.authorMeintjes, Graeme
dc.contributor.authorHughes, Jennifer
dc.contributor.authorMaartens, Gary
dc.contributor.authorFerreira, Hannetjie
dc.contributor.authorSiwendu, Sweetness
dc.contributor.authorMaster, Iqbal
dc.contributor.authorNdjeka, Norbert
dc.date.accessioned2021-10-08T07:20:27Z
dc.date.available2021-10-08T07:20:27Z
dc.date.issued2014
dc.description.abstractWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.
dc.identifier.apacitationConradie, F., Meintjes, G., Hughes, J., Maartens, G., Ferreira, H., Siwendu, S., ... Ndjeka, N. (2014). Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis. <i>South African Medical Journal</i>, 104(3), 164 - 177. http://hdl.handle.net/11427/34919en_ZA
dc.identifier.chicagocitationConradie, Francesca, Graeme Meintjes, Jennifer Hughes, Gary Maartens, Hannetjie Ferreira, Sweetness Siwendu, Iqbal Master, and Norbert Ndjeka "Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis." <i>South African Medical Journal</i> 104, 3. (2014): 164 - 177. http://hdl.handle.net/11427/34919en_ZA
dc.identifier.citationConradie, F., Meintjes, G., Hughes, J., Maartens, G., Ferreira, H., Siwendu, S., Master, I. & Ndjeka, N. et al. 2014. Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis. <i>South African Medical Journal.</i> 104(3):164 - 177. http://hdl.handle.net/11427/34919en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - Conradie, Francesca AU - Meintjes, Graeme AU - Hughes, Jennifer AU - Maartens, Gary AU - Ferreira, Hannetjie AU - Siwendu, Sweetness AU - Master, Iqbal AU - Ndjeka, Norbert AB - While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme. DA - 2014 DB - OpenUCT DP - University of Cape Town IS - 3 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2014 SM - 0038-2469 T1 - Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis TI - Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis UR - http://hdl.handle.net/11427/34919 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34919
dc.identifier.vancouvercitationConradie F, Meintjes G, Hughes J, Maartens G, Ferreira H, Siwendu S, et al. Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis. South African Medical Journal. 2014;104(3):164 - 177. http://hdl.handle.net/11427/34919.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Medicine
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue3
dc.source.journalvolume104
dc.source.pagination164 - 177
dc.source.urihttps://dx.doi.org/10.7196/SAMJ.7263
dc.subject.otherDiarylquinolines
dc.subject.otherHealth Services Accessibility
dc.subject.otherHumans
dc.subject.otherSouth Africa
dc.subject.otherTuberculosis, Multidrug-Resistant
dc.subject.otherDiarylquinolines
dc.subject.otherbedaquiline
dc.titleClinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ConradieFrancesca_Clinical_Access_2014.pdf
Size:
89.41 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles